1H-imidazo[4,5-C]quinoline derivatives in the treatment of protein kinase dependent diseases

Details for Australian Patent Application No. 2004295062 (hide)

Owner Novartis AG

Inventors Capraro, Hans-Georg; Furet, Pascal; Stauffer, Frederic; Garcia-Echeverria, Carlos

Agent Davies Collison Cave

Pub. Number AU-B-2004295062

PCT Pub. Number WO2005/054238

Priority 60/524,214 21.11.03 US

Filing date 19 November 2004

Wipo publication date 16 June 2005

Acceptance publication date 4 June 2009

International Classifications

A61K 31/41 (2006.01) - having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

Event Publications

18 May 2006 PCT application entered the National Phase

  PCT publication WO2005/054238 Priority application(s): WO2005/054238

4 June 2009 Application Accepted

  Published as AU-B-2004295062

1 October 2009 Standard Patent Sealed

16 June 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004295078-Method for separating Pb and Ni from co-containing mixtures

2004295061-1H-imidazoquinoline derivatives as protein kinase inhibitors